Cargando…

Drug–Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C

Hepatitis C is a major health problem worldwide, frequently resulting in cirrhosis and increasing the risk of hepatocellular carcinoma significantly. In recent years, the advent of direct-acting antivirals (DAAs) has dramatically improved the therapeutic outcomes in hepatitis C patients. In the last...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Lu-Hua, Nie, Qing-He, Zhao, Xi-Tai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850569/ https://www.ncbi.nlm.nih.gov/pubmed/33536776 http://dx.doi.org/10.2147/IJGM.S283910

Ejemplares similares

Review of Clinically Relevant Drug Interactions with Next Generation Hepatitis C Direct-acting Antiviral Agents
por: Hong, Jenny, et al.
Publicado: (2020)

Drug-drug interactions with direct-acting antivirals — less is more
por: Wong, Grace Lai-Hung
Publicado: (2021)

Drug-drug interactions between direct-acting antivirals and statins in the treatment of chronic hepatitis C
por: Kuo, Meng-Hsuan, et al.
Publicado: (2020)

Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis
por: Hsu, Po-Yao, et al.
Publicado: (2021)

Drug–Drug Interactions between Direct Oral Anticoagulants and Hepatitis C Direct-Acting Antiviral Agents: Looking for Evidence Through a Systematic Review
por: Bellesini, Marta, et al.
Publicado: (2020)

HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
por: Rice, Donald P., et al.
Publicado: (2016)

Drug–Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications
por: Smolders, E. J., et al.
Publicado: (2016)

Impact of Drug Use Policy on the Appropriate Use of Direct Acting Antiviral Agents for Hepatitis C in Saudi Arabia
por: Alotaibi, Ahmed Saqer, et al.
Publicado: (2021)

Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
por: McGlynn, Elizabeth A., et al.
Publicado: (2019)

Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir
por: Badri, Prajakta S., et al.
Publicado: (2015)

Direct-Acting Antiviral Agents for Hepatitis C Virus Infection—From Drug Discovery to Successful Implementation in Clinical Practice
por: Dietz, Christopher, et al.
Publicado: (2022)

Hepatitis-Induced Porphyria: Are Direct-Acting Antiviral Agents the Way of the Future?
por: John, Jason J., et al.
Publicado: (2021)

Drug-drug interactions between antithrombotics and direct-acting antivirals in hepatitis C virus (HCV) patients: A brief, updated report
por: Canonico, Mario Enrico, et al.
Publicado: (2022)

Direct-Acting Antiviral Drugs Reduce Fibromyalgia Symptoms in Patients with Chronic Hepatitis C
por: Tang, Kuo-Tung, et al.
Publicado: (2022)

Direct-acting Antivirals and Host-targeting Agents against the Hepatitis A Virus
por: Kanda, Tatsuo, et al.
Publicado: (2015)

Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection
por: Kanda, Tatsuo, et al.
Publicado: (2014)

Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis
por: Toshikuni, Nobuyuki
Publicado: (2017)

Direct-acting antiviral agents against hepatitis C virus and lipid metabolism
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents
por: Ghweil, Ali A, et al.
Publicado: (2019)

IP-10 Interferes With the Antiviral Response of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection
por: Wang, Yadong, et al.
Publicado: (2022)

Hepatocellular carcinoma after direct‐acting antiviral drug treatment in patients with hepatitis C virus
por: Kogiso, Tomomi, et al.
Publicado: (2018)

The efficacy and safety of direct-acting antiviral drugs in the management of hepatitis C virus-related arthritis
por: Alian, Samah M., et al.
Publicado: (2020)

Antiviral Activity of Approved Antibacterial, Antifungal, Antiprotozoal and Anthelmintic Drugs: Chances for Drug Repurposing for Antiviral Drug Discovery
por: Abdulaziz, Leena, et al.
Publicado: (2022)

Hepatitis C Virus Cell-Cell Transmission and Resistance to Direct-Acting Antiviral Agents
por: Xiao, Fei, et al.
Publicado: (2014)

Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents
por: Zanaga, L.P., et al.
Publicado: (2016)

Hypozincemia in Chronic Hepatitis C Is Improved with Viral Clearance by Direct-acting Antiviral Agents
por: Shirahashi, Ryosaku, et al.
Publicado: (2021)

Factors Associated with the Refusal of Direct-Acting Antiviral Agents for the Treatment of Hepatitis C in Taiwan
por: Chang, Li-Jen, et al.
Publicado: (2022)

The Impact of Direct-Acting Antiviral Agents on Cytomegalovirus Reactivation in Chronic Hepatitis C Infection
por: Dawood, Reham M, et al.
Publicado: (2022)

Interferon-Free Regimens and Direct-Acting Antiviral Agents for Delta Hepatitis: Are We There Yet?
por: Nemteanu, Roxana, et al.
Publicado: (2023)

Impact of Treatment with Direct Acting Antiviral Drugs on Glycemic Control in Patients with Hepatitis C and Diabetes Mellitus
por: Mada, Pradeep Kumar, et al.
Publicado: (2020)

Effectiveness of direct-acting antiviral drugs against hepatitis C virus: predictive factors of response to the treatment
por: Cárdaba-García, María E., et al.
Publicado: (2021)

Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C
por: Brzdęk, Michał, et al.
Publicado: (2023)

Molecular Mechanisms of Resistance to Direct-Acting Antiviral (DAA) Drugs for the Treatment of Hepatitis C Virus Infections
por: Izhari, Mohammad Asrar
Publicado: (2023)

Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: a retrospective observational study
por: Curry, Michael P, et al.
Publicado: (2021)

Drug Interactions in Lenacapavir-Based Long-Acting Antiviral Combinations
por: Cilento, Maria E., et al.
Publicado: (2022)

Direct-Acting Antiviral Drugs and Occurrence of Hepatocellular Carcinoma: Unjust or Oppressed
por: Hassany, Sahar M, et al.
Publicado: (2020)

Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents
por: Kamal, Sanaa M
Publicado: (2014)

SASLT Position Statement on the Direct-Acting Antiviral Agents for the Treatment of Hepatitis C Virus Infection
por: Alghamdi, Abdullah S., et al.
Publicado: (2015)

Hepatitis C in healthcare personnel: secondary data analysis of therapies with direct-acting antiviral agents
por: Westermann, Claudia, et al.
Publicado: (2018)

Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates
por: Gadiparthi, Chiranjeevi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_m2rfrgle4gitctqih0a58ebk5g